Placebo + Ranolazine
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Long QT Syndrome
Conditions
Long QT Syndrome
Trial Timeline
Sep 1, 2012 → Jul 20, 2018
NCT ID
NCT01648205About Placebo + Ranolazine
Placebo + Ranolazine is a phase 2 stage product being developed by Gilead Sciences for Long QT Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01648205. Target conditions include Long QT Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01648205 | Phase 2 | Completed |
Competing Products
16 competing products in Long QT Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ensitrelvir | Shionogi | Phase 2 | 52 |
| TBM100 | Novartis | Approved | 85 |
| GS-6615 + Placebo to match GS-6615 + Placebo to match dofetilide + Dofetilide | Gilead Sciences | Phase 1 | 32 |
| Eleclazine | Gilead Sciences | Phase 1 | 32 |
| Eleclazine | Gilead Sciences | Phase 1 | 32 |
| GS-6615 | Gilead Sciences | Phase 1 | 32 |
| Eleclazine + Eleclazine placebo | Gilead Sciences | Phase 3 | 76 |
| Nirmatrelvir + Ritonavir + Placebo | Pfizer | Phase 2 | 51 |
| Staccato alprazolam | UCB | Phase 3 | 74 |
| Staccato alprazolam | UCB | Phase 3 | 74 |
| N-803 (IL-15 Superagonist) | ImmunityBio | Phase 2 | 49 |
| Anktiva | ImmunityBio | Phase 2 | 49 |
| UX007 | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| triheptanoin | Ultragenyx Pharmaceutical | Pre-clinical | 18 |
| Triheptanoin | Ultragenyx Pharmaceutical | Phase 3 | 72 |
| Triheptanoin | Ultragenyx Pharmaceutical | Pre-clinical | 18 |